MARKET

CNTG

CNTG

Centogene N.V.
NASDAQ
0.6900
-0.0285
-3.97%
Closed 16:23 03/27 EDT
OPEN
0.6800
PREV CLOSE
0.6900
HIGH
0.7499
LOW
0.6000
VOLUME
781.56K
TURNOVER
0
52 WEEK HIGH
2.520
52 WEEK LOW
0.6000
MARKET CAP
19.23M
P/E (TTM)
-0.7206
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CNTG last week (0318-0322)?
Weekly Report · 3d ago
Centogene, Takeda extend diagnostic partnership
Healthcare Centogene, Takeda extend diagnostic partnership. German biotech will continue to provide its testing solutions to the Japanese pharma giant. The two companies will work together to diagnose patients with inherited metabolic diseases. CNTG and TAK first established a partnership in 2015.
Seeking Alpha · 03/19 11:41
CENTOGENE and Takeda Boost Genetic Testing for LSDs
TipRanks · 03/19 11:28
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
Centogene extends partnership with Takeda to diagnose patients with Lysosomal Storage Disorders. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome. CENTOGENE will continue to provide access to testing for patients around the world.
Benzinga · 03/19 10:32
Weekly Report: what happened at CNTG last week (0311-0315)?
Weekly Report · 03/18 11:30
Weekly Report: what happened at CNTG last week (0304-0308)?
Weekly Report · 03/11 11:26
Weekly Report: what happened at CNTG last week (0226-0301)?
Weekly Report · 03/04 11:29
Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge
Healthcare Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge Feb. 28. CNTG -18.75% premarket to $0.77. Centogene (CNTG) received a staff determination letter from Nasdaq on Feb. 27 to delist the company's securities.
Seeking Alpha · 02/28 12:18
More
About CNTG
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Webull offers Centogene NV stock information, including NASDAQ: CNTG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTG stock methods without spending real money on the virtual paper trading platform.